BioXcel Therapeutics Announces Positive FDA Pre-sNDA Meeting Comments for sNDA Submission for BXCL501 in Agitation Associated with Bipolar Disorders or Schizophrenia
BioXcel Therapeutics (NASDAQ: BTAI) has received positive pre-sNDA meeting feedback from the FDA regarding the potential expansion of IGALMI's (BXCL501) label for at-home use in treating agitation associated with bipolar disorders or schizophrenia. The company plans to submit the sNDA in Q1 2026.
The FDA's feedback confirms agreement on the content and format of the planned submission, including clinical, nonclinical, and CMC requirements. The regulatory package will include data from the Phase 3 SERENITY At-Home trial, a 12-week study evaluating the safety of 120 mcg BXCL501 dose. IGALMI is currently approved for use in medically supervised settings and is available in 120 mcg and 180 mcg doses.
Notably, BXCL501 has received Fast Track Designation, and there are currently no FDA-approved therapies for acute agitation treatment in the at-home setting.
BioXcel Therapeutics (NASDAQ: BTAI) ha ricevuto un riscontro positivo dalla FDA in sede di pre-incontro sNDA riguardo alla possibile estensione dell'indicazione di IGALMI (BXCL501) per l'uso domiciliare nel trattamento dell'agitazione associata a disturbi bipolari o alla schizofrenia. L'azienda prevede di presentare la sNDA nel Q1 2026.
La FDA ha confermato l'accordo sul contenuto e sul formato della submission prevista, incluse le richieste cliniche, non cliniche e CMC. Il dossier regolatorio comprenderà i dati del Phase 3 SERENITY At-Home trial, uno studio di 12 settimane che valuta la sicurezza della dose di 120 mcg di BXCL501. IGALMI è attualmente approvato per l'uso in contesti clinici supervisionati ed è disponibile nelle dosi da 120 mcg e 180 mcg.
È importante notare che BXCL501 ha ottenuto la Fast Track Designation e al momento non esistono terapie approvate dalla FDA per il trattamento dell'agitazione acuta in ambiente domiciliare.
BioXcel Therapeutics (NASDAQ: BTAI) recibió comentarios favorables de la FDA en la reunión previa a la sNDA sobre la posible ampliación de la etiqueta de IGALMI (BXCL501) para uso domiciliario en el tratamiento de la agitación asociada a trastornos bipolares o esquizofrenia. La compañía planea presentar la sNDA en el Q1 2026.
La FDA confirmó el acuerdo sobre el contenido y el formato de la presentación prevista, incluidos los requisitos clínicos, no clínicos y de CMC. El paquete regulatorio incluirá datos del Phase 3 SERENITY At-Home trial, un estudio de 12 semanas que evalúa la seguridad de la dosis de 120 mcg de BXCL501. IGALMI está actualmente aprobado para uso en entornos médicamente supervisados y está disponible en dosis de 120 mcg y 180 mcg.
Cabe destacar que BXCL501 ha recibido la Fast Track Designation y actualmente no existen terapias aprobadas por la FDA para el tratamiento de la agitación aguda en el entorno domiciliario.
BioXcel Therapeutics (NASDAQ: BTAI)는 가정 내 사용을 위한 IGALMI(BXCL501) 적응증 확대 가능성에 대해 FDA와의 사전 sNDA 회의에서 긍정적인 피드백을 받았습니다. 회사는 2026년 1분기(Q1 2026)에 sNDA 제출을 계획하고 있습니다.
FDA는 임상, 비임상 및 CMC 요건을 포함한 예정 제출서의 내용과 형식에 대해 합의가 이루어졌음을 확인했습니다. 규제 패키지에는 BXCL501 120 mcg 용량의 안전성을 평가한 12주간의 Phase 3 SERENITY At-Home trial 데이터가 포함될 예정입니다. IGALMI는 현재 의료 감독 하의 환경에서 사용하도록 승인되어 있으며 120 mcg 및 180 mcg 용량으로 제공됩니다.
특히 BXCL501는 Fast Track Designation을 받았으며, 현재 가정 환경에서 급성 불안을 치료하기 위한 FDA 승인 치료제는 없습니다.
BioXcel Therapeutics (NASDAQ: BTAI) a reçu un retour positif de la FDA lors de la réunion pré-sNDA concernant l'élargissement potentiel de l'autorisation de IGALMI (BXCL501) pour une utilisation à domicile dans le traitement de l'agitation associée aux troubles bipolaires ou à la schizophrénie. La société prévoit de déposer la sNDA au 1er trimestre 2026 (Q1 2026).
La FDA a confirmé l'accord sur le contenu et le format de la soumission prévue, y compris les exigences cliniques, non cliniques et CMC. Le dossier réglementaire comprendra les données de l'essai de phase 3 SERENITY At-Home, une étude de 12 semaines évaluant la sécurité de la dose de 120 mcg de BXCL501. IGALMI est actuellement approuvé pour une utilisation dans des contextes médicalement supervisés et est disponible aux doses de 120 mcg et 180 mcg.
Il est notable que BXCL501 a obtenu la Fast Track Designation et qu'il n'existe actuellement aucune thérapie approuvée par la FDA pour le traitement de l'agitation aiguë en milieu domiciliaire.
BioXcel Therapeutics (NASDAQ: BTAI) hat von der FDA im Rahmen eines Pre-sNDA-Meetings positives Feedback hinsichtlich der möglichen Erweiterung der Zulassung von IGALMI (BXCL501) für die Anwendung zu Hause bei Agitation im Zusammenhang mit bipolaren Störungen oder Schizophrenie erhalten. Das Unternehmen plant, die sNDA im Q1 2026 einzureichen.
Die FDA bestätigte die Übereinstimmung hinsichtlich Inhalt und Format der geplanten Einreichung, einschließlich klinischer, nichtklinischer und CMC-Anforderungen. Das Zulassungspaket wird Daten aus der Phase 3 SERENITY At-Home trial enthalten, einer 12-wöchigen Studie zur Bewertung der Sicherheit der 120‑mcg‑Dosis von BXCL501. IGALMI ist derzeit für die Anwendung unter medizinischer Aufsicht zugelassen und in den Dosierungen 120 mcg und 180 mcg erhältlich.
Bemerkenswert ist, dass BXCL501 die Fast Track Designation erhalten hat und derzeit keine von der FDA zugelassenen Therapien für die Behandlung akuter Agitation im häuslichen Umfeld existieren.
- Positive FDA feedback on planned sNDA submission content and format
- Fast Track Designation status for BXCL501
- First-mover advantage with no current FDA-approved therapies for at-home agitation treatment
- Potential market expansion from supervised settings to at-home use
- Final sNDA submission and approval still pending
- Topline trial data not yet released
- Extended timeline with sNDA submission planned for Q1 2026
Insights
FDA alignment on BioXcel's sNDA package for IGALMI's at-home use represents significant regulatory advancement toward label expansion.
BioXcel has cleared a critical regulatory milestone in its pursuit to expand IGALMI's (BXCL501) label to include at-home use for agitation in bipolar disorders and schizophrenia. The FDA's positive pre-sNDA meeting comments suggest the company's planned submission package contains the necessary elements for regulatory review. This is particularly significant as it potentially transforms IGALMI from a medication restricted to medically supervised settings into one that can be used in outpatient environments.
The regulatory strategy appears well-executed, with the company building on previous interactions with the FDA, including a Type C Meeting in March 2024 where trial design was agreed upon. The planned Q1 2026 submission timeline remains intact, and the Fast Track Designation could accelerate the review process once submitted.
What's especially notable is that BioXcel is targeting an unmet medical need – there are currently no FDA-approved therapies for acute agitation treatment in at-home settings for these psychiatric conditions. The pivotal Phase 3 SERENITY At-Home trial has completed with topline data expected this month, which will be crucial for the submission package. If positive, this would represent the final clinical piece needed for the sNDA filing.
The company's focus on the lower 120 mcg dose for the at-home setting (versus the 120 mcg and 180 mcg approved for supervised settings) reflects appropriate risk management for self-administration, which likely helped secure FDA alignment on the submission package.
Achieved alignment with the FDA on sNDA package to expand the IGALMI label for the At-Home (Outpatient) setting
sNDA submission on track for Q1 2026
NEW HAVEN, Conn., Aug. 18, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that it has received positive pre-sNDA meeting responses from the U.S. Food and Drug Administration (FDA). Based on the FDA’s feedback, the Company believes that the planned sNDA regulatory package will be sufficient to support the sNDA submission, which remains on track for the first quarter of 2026.
The primary purpose of the planned meeting was to gain alignment with the FDA regarding the content and format of the Company’s planned supplemental New Drug Application (sNDA) submission for the at-home (outpatient) use of BXCL501, including the clinical, nonclinical, and chemistry and manufacturing and controls (CMC) requirements. The Company concludes that the objectives of the pre-sNDA meeting have been accomplished based on the FDA’s written responses and has determined that the meeting, originally scheduled for August 20, 2025, is no longer required. The pre-sNDA preliminary meeting comments received from FDA on August 14, 2025, will serve as the official record. Acceptance of the sNDA will be subject to the FDA’s review of the complete filing.
“We are pleased with the pre-sNDA meeting feedback we received from the FDA, which confirmed agreement on the content and format for our planned sNDA submission, and reflects a shared commitment to addressing the urgent needs of patients living with bipolar disorder or schizophrenia,” said Vimal Mehta, Ph.D., CEO of BioXcel Therapeutics. “This marks an important milestone in our mission to bring a safe and effective outpatient treatment to patients suffering from agitation, potentially transforming the treatment paradigm.”
IGALMI is currently FDA-approved and marketed for the acute treatment of agitation associated with bipolar I or II disorder or schizophrenia in medically supervised settings. IGALMI is available in 2 dose strengths, 120 mcg and 180 mcg. To support the potential label expansion for at-home use, an important part of the regulatory package will be data from the pivotal Phase 3 SERENITY At-Home trial, which is a double-blind, placebo-controlled 12-week study designed to evaluate the safety of a 120 mcg dose of BXCL501 for the acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home setting. The trial design and protocol were agreed with FDA at a Type C Meeting held in March 2024. The Company recently announced the completion of the last patient last visit (LPLV), with topline data expected this month.
BXCL501 was granted Fast Track Designation for the acute treatment of agitation associated with bipolar disorders or schizophrenia. There are no FDA-approved therapies for the acute treatment of agitation in the at-home setting.
About the SERENITY At-Home Phase 3 Trial
The SERENITY At-Home Phase 3 trial is a double-blind, placebo-controlled study designed to evaluate the safety of a 120 mcg dose of BXCL501 for the acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home setting. The trial is designed to evaluate 200 patients with a history of agitation episodes residing at home either alone or with caregivers/informants. Patients are self-administering 120 mcg of BXCL501 or placebo when agitation episodes occur over the 12-week trial period, with safety data (adverse events) collected during the trial. In addition, patients or caregivers/informants complete a modified global impression of severity (mCGIs) and a clinical global impression of change (mCGI-C) two hours after dosing as an exploratory endpoint to evaluate use in the outpatient setting.
About BXCL501
Outside of its approved indication by the U.S. Food and Drug Administration as IGALMI® (dexmedetomidine) sublingual film, BXCL501 is an investigational proprietary, orally dissolving film formulation of dexmedetomidine, a selective alpha-2 adrenergic receptor agonist. BXCL501 is under investigation by BioXcel Therapeutics for the acute treatment of agitation associated with Alzheimer’s dementia and for the acute treatment of agitation associated with bipolar I or II disorder or schizophrenia in the at-home setting. The safety and efficacy of BXCL501 for these investigational uses have not been established. BXCL501 has been granted Breakthrough Therapy designation by the FDA for the acute treatment of agitation associated with dementia and Fast Track designation for the acute treatment of agitation associated with schizophrenia, bipolar disorders, and dementia.
About IGALMI® (dexmedetomidine) sublingual film
INDICATION
IGALMI® (dexmedetomidine) sublingual film is a prescription medicine, administered under the supervision of a health care provider, that is placed under the tongue or behind the lower lip and is used for the acute treatment of agitation associated with schizophrenia and bipolar disorder I or II in adults. The safety and effectiveness of IGALMI has not been studied beyond 24 hours from the first dose. It is not known if IGALMI is safe and effective in children.
IMPORTANT SAFETY INFORMATION
IGALMI can cause serious side effects, including:
- Decreased blood pressure, low blood pressure upon standing, and slower than normal heart rate, which may be more likely in patients with low blood volume, diabetes, chronic high blood pressure, and older patients. IGALMI is taken under the supervision of a healthcare provider who will monitor vital signs (like blood pressure and heart rate) and alertness after IGALMI is administered to help prevent falling or fainting. Patients should be adequately hydrated and sit or lie down after taking IGALMI and instructed to tell their healthcare provider if they feel dizzy, lightheaded, or faint.
- Heart rhythm changes (QT interval prolongation). IGALMI should not be given to patients with an abnormal heart rhythm, a history of an irregular heartbeat, slow heart rate, low potassium, low magnesium, or taking other drugs that could affect heart rhythm. Taking IGALMI with a history of abnormal heart rhythm can increase the risk of torsades de pointes and sudden death. Patients should be instructed to tell their healthcare provider immediately if they feel faint or have heart palpitations.
- Sleepiness/drowsiness. Patients should not perform activities requiring mental alertness, such as driving or operating hazardous machinery, for at least 8 hours after taking IGALMI.
- Withdrawal reactions, tolerance, and decreased response/efficacy. IGALMI was not studied for longer than 24 hours after the first dose. Physical dependence, withdrawal symptoms (e.g., nausea, vomiting, agitation), and decreased response to IGALMI may occur if IGALMI is used longer than 24 hours.
The most common side effects of IGALMI in clinical studies were sleepiness or drowsiness, a prickling or tingling sensation or numbness of the mouth, dizziness, dry mouth, low blood pressure, and low blood pressure upon standing.
These are not all the possible side effects of IGALMI. Patients should speak with their healthcare provider for medical advice about side effects.
Patients should tell their healthcare provider about their medical history, including if they suffer from any known heart problems, low potassium, low magnesium, low blood pressure, low heart rate, diabetes, high blood pressure, history of fainting, or liver impairment. They should also tell their healthcare provider if they are pregnant or breastfeeding or take any medicines, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Patients should especially tell their healthcare provider if they take any drugs that lower blood pressure, change heart rate, or take anesthetics, sedatives, hypnotics, and opioids.
Everyone is encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You can also contact BioXcel Therapeutics, Inc. at 1-833-201-1088 or medinfo@bioxceltherapeutics.com.
Please see full prescribing information at Igalmi.com.
About BioXcel Therapeutics, Inc.
BioXcel Therapeutics, Inc. (Nasdaq: BTAI) is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience. Its wholly owned subsidiary, OnkosXcel Therapeutics, is focused on the development of medicines in immuno-oncology. The Company’s drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indications. For more information, please visit bioxceltherapeutics.com.
Forward-Looking Statements
This current report includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this current report other than statements of historical fact should be considered forward-looking statements, including, without limitation, statements related to: the Company’s upcoming top-line data release for the SERENITY At-Home Phase 3 trial, the planned sNDA submission, bringing a safe and effective outpatient treatment to patients suffering from agitation and transforming the treatment paradigm. When used herein, words including “anticipate,” “believe,” “can,” “continue,” “could,” “designed,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon the Company’s current expectations and various assumptions. The Company believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. The Company may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation: its limited operating history; its incurrence of significant losses; its need for substantial additional funding and ability to raise capital when needed; the impact of the reprioritization; its significant indebtedness, ability to comply with covenant obligations and potential payment obligations related to such indebtedness and other contractual obligations; the conditions and events that raise substantial doubt about its ability to continue as a going concern; its limited experience in drug discovery and drug development; risks related to the TRANQUILITY program; its dependence on the success and commercialization of IGALMI™, BXCL501, BXCL502, BXCL701 and BXCL702 and other product candidates; the number of episodes of agitation and the size of the Company’s total addressable market may be overestimated, and approval that the Company may obtain may be based on a narrower definition of the patient population; its lack of experience in marketing and selling drug products; the risk that IGALMI or the Company’s product candidates may not be accepted by physicians or the medical community in general; the Company still faces extensive and ongoing regulatory requirements and obligations for IGALMI; the failure of preliminary data from its clinical studies to predict final study results; failure of its early clinical studies or preclinical studies to predict future clinical studies; its ability to receive regulatory approval for its product candidates; its ability to enroll patients in its clinical trials; undesirable side effects or potential of misuse of the Company’s product candidates that could impact regulatory approval; its novel approach to the discovery and development of product candidates based on EvolverAI or our AI platform; the significant influence of and dependence on BioXcel LLC; failure to maintain compliance with Nasdaq’s listing standards; its exposure to patent infringement lawsuits; its reliance on third parties; its ability to comply with the extensive regulations applicable to it; impacts from data breaches or cyber-attacks, if any; risks associated with the increased scrutiny relating to environmental, social and governance (ESG) matters; risks associated with federal, state or foreign health care “fraud and abuse” laws; and its ability to commercialize its product candidates, as well the factors discussed under the caption “Risk Factors” in its most recent Quarterly Report on Form 10-Q, as such factors may be updated from time to time in its other filings with the SEC. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this current report. While the Company may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this current report.
Contact Information
Corporate/Investors
Russo Partners
Nic Johnson
nic.johnson@russopartnersllc.com
1.303.482.6405
Media
Russo Partners
David Schull
david.schull@russopartnersllc.com
1.858.717.2310
Source: BioXcel Therapeutics, Inc.
IGALMI® is a registered trademark of BioXcel Therapeutics, Inc.
References
- Data on file relating to agitation episodes associated with schizophrenia or bipolar I or II disorder. BioXcel Therapeutics, Inc. New Haven, CT December 2020. Episode estimations may not reflect potential treatable episodes, and actual addressable market may be smaller.
- Data from Wu EQ, Shi L, Birnbaum H, et al. Annual prevalence of diagnosed schizophrenia in the USA: a claims data analysis approach. Psychol Med. 2006;36(11):1535-1540. Estimates based on whether indications are approved for at-home use for the intended patient population and such patients are treatable. Episode estimations may not reflect potential treatable episodes, and actual addressable market may be smaller.
- National Institute of Mental Health. Prevalence of bipolar disorder in adults. November 2017. Accessed December 16, 2022. https://www.nimh.nih.gov/health/statistics/bipolar-disorder. Episode estimations may not reflect potential treatable episodes, and actual addressable market may be smaller.
FAQ
What was the FDA's response to BioXcel's pre-sNDA meeting for BXCL501?
When will BioXcel (BTAI) submit the sNDA for BXCL501's at-home use?
What doses of IGALMI (BXCL501) are currently approved?
What is the SERENITY At-Home trial for BXCL501?
Are there currently any FDA-approved treatments for at-home agitation in bipolar disorder or schizophrenia?
